Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer

The cyclin D-cyclin-dependent kinase (CDK) 4/6 pathway controls the cell cycle machinery by regulating the G1-to-S-phase transition. Dysregulation of this pathway, resulting in increased cellular proliferation, is frequently observed in a variety of human cancers. Activation of cyclin D-CDK 4/6 path...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Tamojit Chaudhuri, K Govind Babu, K C Lakshmaiah, Lokanatha Dasappa, Linu Abraham Jacob, M C Suresh Babu, A H Rudresha, K N Lokesh, L K Rajeev
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-01-01
סדרה:	Indian Journal of Medical and Paediatric Oncology
נושאים:	Abemaciclib palbociclib ribociclib selective cyclin-dependent kinase 4/6 inhibitors
גישה מקוונת:	http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=15;epage=20;aulast=Chaudhuri
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!